Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Editor’s Note: Michael pushed this out to his free Strategic Tech Investor readers last night. Now that they’ve had the chance to get ready, we want to make sure everyone has a chance to cash in here. To get Michael’s free tech and pot stock investing research for yourself each week, just click here. Here he is…
I knew legal cannabis began to step out of the shadows and onto the big stage when some of its largest and best-run firms started listing on major U.S. stock exchanges.
Two Canadian companies have done that so far – uplisting their OTC-traded stocks to one of the big American exchanges.
At the end of February, Cronos Group Inc. (Nasdaq: CRON) uplisted to the Nasdaq, while Canopy Growth Corp. (NYSE: CGC) debuted on the New York Stock Exchange on May 19.
Both of those were big news at the time.
And for a very good reason, as I’ll show you...
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.
WDDMF down over 40 % in just a week, What is going on? will it recover?
Cannabis stocks are Very speculative and volitle.
Watch them soar, I suggest revisiting your comment.
You have said you like imed very much and all I see is no patents no anything what's up unless I'm wrong imed doesn't look great
Good morning MICHAEL A. ROBINSON, I was watching your videos of cannabis investments. There are still opportunities or it's already too late? ….